Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI - PubMed (original) (raw)

. 1991 Sep 19;353(6341):265-7.

doi: 10.1038/353265a0.

Affiliations

Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI

E M Rubin et al. Nature. 1991.

Abstract

Epidemiological surveys have identified a strong inverse relationship between the amount in the plasma of high density lipoproteins (HDL), apolipoprotein AI (ApoA-I), the major protein component of HDL, and the risk for atherosclerosis in humans. It is not known if this relationship arises from a direct antiatherogenic effect of these plasma components or if it is the result of other factors also associated with increases in ApoA-I and HDL levels. Because some strains of mice are susceptible to diet-induced formation of preatherosclerotic fatty streak lesions, and because of available techniques for the genetic manipulation of this organism, the murine system offers a unique setting in which to investigate the process of early atherogenesis. To test the hypothesis that induction of a high plasma concentration of ApoA-I and HDL would inhibit this process, we studied the effects of atherogenic diets on transgenic mice expressing high amounts of human ApoA-I. We report that transgenic mice with high plasma ApoA-I and HDL levels were significantly protected from the development of fatty streak lesions.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources